Prescient Therapeutics Launches Share Purchase Plan for $7m

Key points

• Prescient Therapeutics plans to raise up to $7 million via a Share Purchase Plan at $0.065 per share.
• Funds will advance PTX-100, the Company's first-in-class cancer treatment.
• Share Purchase Plan follows a year of strong operational delivery and clinical trial progress.

Full summary

Prescient Therapeutics (ASX: PTX), a clinical-stage oncology company, has announced a Share Purchase Plan (SPP) to raise up to $7 million. The SPP will offer shares at $0.065 each, an 18.8% discount to the 10-day volume weighted average price. The funds will support the ongoing development of PTX-100, the Company's first-in-class cancer treatment, and general working capital. The SPP follows a year of strong operational delivery, including progress in the Phase 2a clinical trial. A shareholder briefing with CEO James McDonnell is scheduled for August 28th.

Guidance

Prescient Therapeutics aims to raise up to $7 million via the SPP.

Outlook

The funds raised will support the advancement of PTX-100 through clinical development and potentially into regulatory approval.